Michael Mingueneau
Vice President, Immunology Sail Biomedicines
Seminars
Thursday 28th May 2026
Programming T Cells In Vivo with Targeted Nanoparticles Encapsulating eRNATM-encoded hCD19 CAR for Transient Activation to Achieve Deep B-cell Depletion and Immune Reset
1:00 pm
- Applying Circular & Self- Amplifying RNA to Enable In Vivo CAR-T & Replace Complex Ex Vivo Cell Therapies with Scalable Immune Modulation
- In vivo CAR-T cell engineering has the potential to transform the care of patients with autoimmune diseases by simplifying and broadening access to treatments with potential for cures
- Sail’s in vivo CAR-T drug candidate (DC) has been engineered and extensively optimized to achieve an optimal dose efficiency profile and ultimately therapeutic index in patients with autoimmune conditions. As a result, Sail’s in vivo CAR-T DC is able to achieve deep tissue depletion of B cells and effectively reset the B cell compartment at low dose levels
- Sail’s in vivo CAR-T DC has the potential to replace complex, costly, and genome-integrative cell therapy products with an off-the-shelf and non-integrative IV injectable product that avoids the safety risks associated with lymphoablative conditioning
Wednesday 27th May 2026
Fireside Chat: Interrogating Next-Generation RNA Value Propositions to Define True Advantage Beyond Linear mRNA & Accelerate Clinical Adoption
9:00 am
- Clarify which benefits justify moving beyond linear mRNA, and how to differentiate next-gen RNA platforms to secure stakeholder buy-in
- Pinpoint structural reasons clinical translation has lagged expectations to avoid repeat failures and sharpen value propositions
- Define where circRNA or saRNA genuinely outperform existing modalities to strengthen investment cases and stand out in a crowded landscape
